These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 28975463

  • 1. Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis: a retrospective cohort study.
    Nakazawa M, Kaneko Y, Takeuchi T.
    Clin Rheumatol; 2018 Mar; 37(3):765-771. PubMed ID: 28975463
    [Abstract] [Full Text] [Related]

  • 2. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
    Hozumi H, Fujisawa T, Nakashima R, Johkoh T, Sumikawa H, Murakami A, Enomoto N, Inui N, Nakamura Y, Hosono Y, Imura Y, Mimori T, Suda T.
    Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
    [Abstract] [Full Text] [Related]

  • 3. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
    Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Watanabe K, Aihara K, Ikezoe K, Sokai A, Nakatsuka Y, Taguchi Y, Hatta K, Noma S, Kobashi Y, Yoshizawa A, Oga T, Hirai T, Chin K, Nagai S, Izumi T, Mimori T, Mishima M.
    Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
    [Abstract] [Full Text] [Related]

  • 4. Clinical characteristics of dermatomyosits/polymyositis associated interstitial lung disease according to the autoantibody.
    Kishaba T, McGill R, Nei Y, Ibuki S, Momose M, Nishiyama K, Nagano H, Yamashiro S.
    J Med Invest; 2018 Jun; 65(3.4):251-257. PubMed ID: 30282869
    [Abstract] [Full Text] [Related]

  • 5. Pulmonary manifestations of anti-ARS antibody positive interstitial pneumonia--with or without PM/DM.
    Takato H, Waseda Y, Watanabe S, Inuzuka K, Katayama N, Ichikawa Y, Yasui M, Fujimura M.
    Respir Med; 2013 Jan; 107(1):128-33. PubMed ID: 23137883
    [Abstract] [Full Text] [Related]

  • 6. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
    Yoshida N, Okamoto M, Kaieda S, Fujimoto K, Ebata T, Tajiri M, Nakamura M, Tominaga M, Wakasugi D, Kawayama T, Kuwana M, Mimori T, Ida H, Hoshino T.
    Respir Investig; 2017 Jan; 55(1):24-32. PubMed ID: 28012490
    [Abstract] [Full Text] [Related]

  • 7. Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study.
    Hozumi H, Enomoto N, Kono M, Fujisawa T, Inui N, Nakamura Y, Sumikawa H, Johkoh T, Nakashima R, Imura Y, Mimori T, Suda T.
    PLoS One; 2015 Jan; 10(3):e0120313. PubMed ID: 25789468
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis/dermatomyositis-associated Interstitial Lung Disease: A Propensity Score-matched Analysis.
    Hozumi H, Fujisawa T, Nakashima R, Yasui H, Suzuki Y, Kono M, Karayama M, Furuhashi K, Enomoto N, Inui N, Nakamura Y, Mimori T, Suda T.
    J Rheumatol; 2019 May; 46(5):509-517. PubMed ID: 30647164
    [Abstract] [Full Text] [Related]

  • 9. Clinical characteristics of patients with anti-aminoacyl-tRNA synthetase antibody positive idiopathic interstitial pneumonia.
    Yura H, Sakamoto N, Satoh M, Ishimoto H, Hanaka T, Ito C, Hasegawa T, Tanaka S, Miyamura T, Nakashima S, Hara A, Kakugawa T, Oda K, Kido T, Obase Y, Ishimatsu Y, Yatera K, Kawakami A, Mukae H.
    Respir Med; 2017 Nov; 132():189-194. PubMed ID: 29229096
    [Abstract] [Full Text] [Related]

  • 10. Comparison of cytokine profiles between anti-ARS antibody-positive interstitial lung diseases and those with anti-MDA-5 antibodies.
    Asakawa K, Yoshizawa K, Aoki A, Kimura Y, Tanaka T, Ohashi K, Hayashi M, Kikuchi T, Sato S, Takada T.
    Clin Rheumatol; 2020 Jul; 39(7):2171-2178. PubMed ID: 32056068
    [Abstract] [Full Text] [Related]

  • 11. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease.
    Gono T, Kaneko H, Kawaguchi Y, Hanaoka M, Kataoka S, Kuwana M, Takagi K, Ichida H, Katsumata Y, Ota Y, Kawasumi H, Yamanaka H.
    Rheumatology (Oxford); 2014 Dec; 53(12):2196-203. PubMed ID: 24970922
    [Abstract] [Full Text] [Related]

  • 12. [Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases].
    Xie MM, Zou RY, Li Y, Liu Y, Chen LL, Liu XQ, Zhao Q, Ding JJ, Chen ZY, Cai HR.
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Oct 12; 42(10):765-770. PubMed ID: 31594111
    [Abstract] [Full Text] [Related]

  • 13. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies.
    Yoshifuji H, Fujii T, Kobayashi S, Imura Y, Fujita Y, Kawabata D, Usui T, Tanaka M, Nagai S, Umehara H, Mimori T.
    Autoimmunity; 2006 May 12; 39(3):233-41. PubMed ID: 16769657
    [Abstract] [Full Text] [Related]

  • 14. Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis.
    Matsushita T, Hasegawa M, Fujimoto M, Hamaguchi Y, Komura K, Hirano T, Horikawa M, Kondo M, Orito H, Kaji K, Saito Y, Matsushita Y, Kawara S, Yasui M, Seishima M, Ozaki S, Kuwana M, Ogawa F, Sato S, Takehara K.
    J Rheumatol; 2007 May 12; 34(5):1012-8. PubMed ID: 17309126
    [Abstract] [Full Text] [Related]

  • 15. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome.
    Hamaguchi Y, Fujimoto M, Matsushita T, Kaji K, Komura K, Hasegawa M, Kodera M, Muroi E, Fujikawa K, Seishima M, Yamada H, Yamada R, Sato S, Takehara K, Kuwana M.
    PLoS One; 2013 May 12; 8(4):e60442. PubMed ID: 23573256
    [Abstract] [Full Text] [Related]

  • 16. Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?
    Lega JC, Cottin V, Fabien N, Thivolet-Béjui F, Cordier JF.
    J Rheumatol; 2010 May 12; 37(5):1000-9. PubMed ID: 20231208
    [Abstract] [Full Text] [Related]

  • 17. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.
    Enomoto Y, Suzuki Y, Hozumi H, Mori K, Kono M, Karayama M, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Suzuki D, Ogawa N, Nakashima R, Mimori T, Iwashita T, Suda T.
    Arthritis Res Ther; 2017 Jan 19; 19(1):9. PubMed ID: 28103926
    [Abstract] [Full Text] [Related]

  • 18. Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies.
    Chen F, Li S, Wang T, Shi J, Wang G.
    Am J Med Sci; 2018 Jan 19; 355(1):48-53. PubMed ID: 29289262
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of usefulness in surfactant protein D as a predictor of mortality in myositis-associated interstitial lung disease.
    Kaieda S, Gono T, Masui K, Nishina N, Sato S, Kuwana M, A Multicenter Retrospective Cohort of Japanese Patients with Myositis-associated ILD (JAMI) investigators.
    PLoS One; 2020 Jan 19; 15(6):e0234523. PubMed ID: 32525903
    [Abstract] [Full Text] [Related]

  • 20. Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China.
    Zhan X, Yan W, Wang Y, Li Q, Shi X, Gao Y, Ye Q.
    BMC Pulm Med; 2021 Feb 12; 21(1):57. PubMed ID: 33579248
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.